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390Key words: CD56; natural killer/T cell; rituximab; T cell lymphoma.Abbreviations used:
EBER: Epstein-Barr viruseencoded small
RNAs
EBV: Epstein-Barr virus
ENKTL: extranodal natural killer/T-cell
lymphoma
NK: natural killer
PET/CT: positron emission tomography/
computed tomography
R-CHOP: cyclophosphamide, Adriamycin,
vincristine, prednisone, plus rituximab
R-ICE: ifosfamide, carboplatin, and etoposide
plus rituximabINTRODUCTION
Extranodal natural killer (NK)/T-cell lymphoma,
nasal type (ENKTL) rarely presents in the skin, with a
relative frequency of less than 1% among primary
cutaneous lymphomas.1 It is most prevalent among
Asian and South American natives.2 Plaques or
tumors located on the trunk are the most common
presentation.3 The prognosis is grave with a median
survival time of 15 months from the time of diag-
nosis.4 We present a case of CD56 ENKTL manifest-
ing as 2 ulcers on the extremities of a white man.SMILE: L-asparaginase, ifosfamide, metho-
trexate, etoposide, and dexamethasone
TCR: T-cell receptor
CASE REPORT
A 61-year-old white man presented with rapidly
enlarging 7- 8-cm tender dome-shaped nodules with
central ulceration and necrosis on the left posterior
calf (Fig 1) and left forearm (not shown). The patient
complained of fatigue and night sweats over the
prior week. The further examination was unremark-
able with no other skin findings or palpable
lymphadenopathy.
Skin biopsy of the left forearm showed a diffuse
and nodular lymphohistiocytic and granulomatous
infiltrate in the superficial and the reticular dermis
centered around skin appendages and blood vessels
(angiocentricity) extending in subcutaneous adipose
tissue (Fig 2, A and B). Repeat biopsy 1 month later
found a thinned epidermis with impending ulcer
with extensive area of necrosis, lymphocyte exocy-
tosis, basal vacuolization, and Civatte bodies (Fig 2,
C ). The dermis showed diffuse sheets of monoto-
nous medium-sized cells with hyperchromatic nuclei
that extended into the epidermis and includedthe Department of Dermatology, University of Pittsburgha
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(Fig 2, D). The infiltrate consisted of predominantly
T cells and some CD201 B cells (Fig 3). Epstein-Barr
virus (EBV)-encoded small RNAs (EBER) were pos-
itive in approximately 75% of the infiltrate. The
atypical lymphocytes stained positively with CD2
and CD3 and exhibited loss of CD7 expression.
Although there were many CD4 (about 75%) and
fewer CD8 (about 25%) cells, the precise phenotype
of the neoplastic cells was difficult to ascertain
because of the numerous admixed reactive T cells.
BF-1 was positive in about 75% of cells. LCA, TIA-1,
and granzyme were positive in 50% of cells. CD5
highlighted background T cells. Ki-67 stained about
50% of the infiltrate. CD30 stained about 30% of the
cells. FOXP3 and CD123 stained about 10% of cells.
CD56 and CD34 were negative and CD57 stained
rare cells. Southern blot did not detect T-cell receptor3708 Fifth Avenue, Pittsburgh, PA 15213. E-mail: akilovoe@
upmc.edu.
JAAD Case Reports 2016;2:390-6.
2352-5126
 2016 by the American Academy of Dermatology, Inc. Published
by Elsevier, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
http://dx.doi.org/10.1016/j.jdcr.2016.05.020
Fig 1. Extranodal NK-T cell presenting with rapidly
expanding cutaneous ulcers in a previously healthy man.
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left forearm, and TCR-g chain rearrangement
was indeterminate with polymerase chain reaction
in the repeat biopsy owing to an inhibitor preventing
amplification. EBV serology found significant
elevation of VCA IgG antibody ([750 U/mL)
and EBV nuclear antigen IgG (537 U/mL). Bone
marrow examination was negative for lymphoma
involvement.
Further evaluation and subsequent staging
included a positron emission tomography (PET)/
computed tomography (CT) scan, which found
increased uptake in the left calf at the place of the
original tumor as well as in tonsils and spleen (Fig 4).
Enlarged lymph nodes were found in the cervical
regions bilaterally; left superior mediastinum; and
the retroperitoneal, splenic, and bilateral inguinal
regions. An ear, nose, and throat examination was
not performed but patient did not exhibit any of
those symptoms.
Initially, after diagnosis, he was treated with
radiation therapy to the lesion on his left leg and
arm, and R-CHOP (cyclophosphamide, Adriamycin,
vincristine, prednisone, plus rituximab). After six
cycles of R-CHOP, he exhibited complete clinical
remission. However, within 6 months, his diseaserecurred with subcutaneous nodules on his left
chest wall, left lateral thigh, and the right scrotum.
He was restarted on R-ICE (ifosfamide, carboplatin,
and etoposide plus rituximab) for 3 cycles. His
disease progressed despite initiation of intrathecal
chemotherapy with depocyt, carmustine, etoposide,
cytarabine, melphalan, and autologous stem cell
transplant. He died 29 months after diagnosis.
DISCUSSION
ENKTL, nasal type, is a rare and aggressive
malignancy. ENKTL accounts for a small minority
of cutaneous lymphomas in the United States, where
the condition is infrequently seen, as most often it
presents in Asia and South America.5 The correct
diagnosis of ENKTL depends on cutaneous and
extracutaneous manifestations, an involvement of
the upper respiratory tract, histologic features, and
immunophenotype.6
The most commonly affected site is the nasal
cavity and nasopharynx.6,7 The skin is involved in
about 26% of cases.8 Currently, the World Health
Organization classification does not make a distinc-
tion for primary cutaneous disease presentation.1,3,9
It is speculated that extranasal and nasal presenta-
tions fall on a spectrum of the same disease, as PET/
CT reveals an occult primary tumor in most cases.8 In
concordance with this statement, our patient’s PET/
CT found tonsillar involvement with enlarged
regional cervical lymph nodes.
ENKTL classically shows an angiocentric and
angiodestructive polymorphic infiltrate of usually
intermediate to larger lymphocytes with often
elongated nuclei, sometimes admixed with other
inflammatory cells and often associated with
necrosis.10 Although the original biopsy found
extensive lymphohistiocytic infiltrate that was not
further evaluated, the repeat biopsy found a more
destructive pattern, typical of ENKTL, with a
perivascular and periadnexal lymphocytic infiltrate
invading the epidermis producing a large area of
necrosis.
ENKTL shows CD2, CD56, and cytoplasmic CD3
positivity. CD56 was negative in our case. CD56 is a
marker for NK cells, expressed in a subset of CD4
and CD8 cells, and is positive in 74% to 76% of cases
of ENKTL.11,12 A definite diagnosis of ENKTL in the
case of CD56 negativity requires EBV positivity and
expression of the cytotoxic proteins such as TIA1,
granzyme B, or perforin.3 Clonal TCR gene rear-
rangement is frequently nondetectable; however, a
subset of tumors in some series do show evidence of
T-cell lineage.13 In this case, the T/NK cell antigen
expression, positive EBER staining, TIA-1 positivity,
granzyme B positivity, and a negative gd stain
Fig 2. Biopsy from the left elbow. Hematoxylin-eosin stain shows a diffuse superficial and
deep dermal infiltrate centered around skin appendages and blood vessels on a scanning (A)
and close-up (B) magnification. A thinned epidermis with impending ulcer with a large area of
necrosis, lymphocyte exocytosis, basal vacuolization, and Civatte bodies (C). Sheets of
monotonous medium-sized cells with hyperchromatic nuclei and included numerous large
atypical lymphocytes (D).
Fig 3. Immunohistochemical staining for CD3 (A), CD20 (B), CD4 (C), CD8 (D), CD43 (E),
CD2 (F), CD5 (G), CD7 (H), EBER (I), Ki-67 (J), CD56 (K), granzyme B (L). CD2, CD3, CD43,
Ki-67, EBER and granzyme B stain strongly. CD4, CD5, CD7, CD8 are somewhat diminished
compared with CD2 and CD3 staining. CD56 is completely absent.
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rearrangement was indeterminate. Whether the
ENKTL reported here is of T cell or NK cell origin
remains therefore undefined but does not impact the
diagnosis.Some investigators suggest that ENKTL with CD56
negativity should be described as a separate subtype,
and some postulate that CD56 negativity is associ-
ated with a more aggressive clinical course.14 In a
retrospective study of 288 patients with early-stage
Fig 4. PET/CT scan image shows avid uptake in the tonsils, right axilla, and left calf.
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rate of the CD561 group was 80.6%, whereas the
CD56 group was 60.8%. Further, CD56 negativity
also was associated with a lower 5- and 10-year
progression-free survival. The case reported here,
together with the previously published cases of
CD56 ENKTL with cutaneous involvement, have
many similarities regarding their clinical presentationand also appear to share a poor prognosis (Table I).
All patients presented with an indurated plaque with
frequent ulceration on the lower extremity.
Histologic examination always found a heavy
angiocentric lymphoid infiltrate with some degree
of angioinvasion.
The differential diagnosis of an isolated necrotic
rapidly evolving ulcer on the lower extremity is quite
Table I. Case reports of CD56 ENKTL with cutaneous involvement
Kim et al21 Chia et al6 Little et al22
Lan et al23
Patient 1
Lan et al23
Patient 2
Lan et al23
Patient 3
Gender Female Male Male Female Male Female
Age, y 35 51 60s 23 19 31
Location Right thigh and upper
arm
Left ankle Left calf Eyelid swelling lower
extremities
Face, trunk, and upper/
lower extremities
Trunk, upper/lower
extremities
Morphology Crusted plaque Necrotic ulcer Nodular plaque Plaques Plaques with ulceration
and subcutaneous
nodules
Plaques
Histology Atypical lymphocytes
with angiocentric
infiltrate. Focal
epidermal and dermal
necrosis.
Atypical lymphocytes
with prominent nuclei
and angiocentric
distribution
Atypical lymphoid cells,
frequent mitosis,
infiltration of blood
vessels
Atypical lymphocytes
with angiocentric
growth and
angioinvasion
Atypical lymphocytes
with angiocentric
growth and
angioinvasion
Atypical lymphocytes
with areas of necrosis
and angioinvasion
Phenotype CD31, CD81, granzyme1,
EBER1, CD4, CD56,
CD20
CD31, CD301, granzyme
B1, TIA11, CD5,
CD56, EBER1
CD21, CD31, CD5,
CD7, CD41/, CD8,
CD30, CD56, TIA11,
ALK, EBER1
Cytoplasmic CD31,
granzyme B1,
perforin1, CD81,
EBER1 CD56, CD4,
CD5, CD20, CD3,
CD68, CD79a,
TdT, MPO
Cytoplasmic CD31,
granzyme B1,
perforin1, EBER1,
CD56, CD4, CD5,
CD8, CD20, CD3,
CD68, CD79a,
TdT, MPO
Cytoplasmic CD31,
granzyme B1,
perforin1, EBER1
CD56, CD4, CD8,
CD5, CD20, CD3,
CD68, CD79a,
TdT, MPO
Treatment Cisplatin-based regimen SMILE, then ifosfamide/
etoposide/
dexamethasone,
then DICE, then
radiotherapy
EPOCH 34, then SMILE
32 then autologous
SCT
CHOP CHOP CHOP
Response Only moderate reduction
in tumor size
SMILE - PD; ifosfamide/
etoposide/
dexamethasone e PR
2 months remission after
EPOCH 32; remission
after SMILE 32
PD Died the day of
treatment
Survival from
diagnosis
3 months and alive at
presentation
9 months and alive at
presentation
6 months and alive after
SCT at presentation
3 mo 9 d
CHOP, Cyclophosphamide, vincristine, doxorubicin, and prednisone; DICE, dexamethasone, ifosfamide, cisplatin, etoposide; EPOCH, etoposide, prednisone, oncovin, cyclophosphamide,
hydroxydaunorubicin; PD, progressive disease; PR, partial response; SCT, stem cell transplantation; SMILE, L-asparaginase, ifosfamide, methotrexate, etoposide, and dexamethasone.
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ential diagnosis to the following lymphomas and
lymphoproliferative disorders: angioimmunoblastic
T-cell lymphoma (although, the EBV1 component is
represented by the B cells and it is usually not
neoplastic; if it is neoplastic, then it is classified as
diffuse large B-cell lymphoma and not as angio-
immunoblastic T-cell lymphoma); lymphomatoid
granulomatosis; EBV1 peripheral T-cell lymphoma,
not otherwise specified; EBV-associated hemo-
phagocytic lymphohistiocytosis; aggressive NK-cell
leukemia; and 2 variants of cutaneous chronic
active EBV infection—hydroa vaccinioformeelike
lymphoproliferative disease (T/NK) and severe
mosquito bite allergy (NK). EBV1 lymphomas (both
B- and T-) of many types can be encountered
in the setting of immune suppression (grouped
as posttransplant lymphoproliferative disorders).
Immunohistochemistry, together with the morpho-
logic and clinical findings, are essential in establishing
the correct diagnosis.
Ann Arbor staging for nodal lymphoma rather than
the classification for mycosis fungoides proposed by
EuropeanOrganization for Research and Treatment of
Cancer is used for staging of ENKTL.15 Because of the
rarity of ENKTL and lack of randomized, controlled
trials, current treatment protocols are consensus
based.15 For limited-stage disease (I/II), single
modality such as radiotherapy or chemotherapy (if a
patient is sufficiently fit) is recommended. Advanced
disease (III/IV) is managed with a pegaspargase-
based chemotherapeutic regimen (gemcitabine,
pegaspargase, cisplatin, and dexamethasone or
DDGP)16 with or without chemoradiation (radiation
and platinum-based chemotherapy) according to
recent recommendations.17 Our patient was treated
6 years ago initially with R-CHOP, which was prior
to the DDGP regimen being reported. Clinical
trials are an alternative option at any stage of
ENKTL. If the patient is eligible, hematopoietic
stem cell transplantation should be considered.9,10
Previous studies confirmed low success rates with
anthracycline-containing regimens. The overexpres-
sion of P-glycoprotein in tumor cells is deemed to be
the cause of chemoresistance and early relapse.18 In
concordance with those data, 3 of 5 CD56 ENKTL
patients responded poorly to CHOP (Table I). Two of
5 patients had some response to SMILE (L-asparagi-
nase, ifosfamide, methotrexate, etoposide, and dexa-
methasone). L-asparaginaseebased regimens such
SMILE have been explored previously for advanced-
stage and relapsed/refractory ENKTL, and significant
responses were observed.19 Recently, pegaspargase-
based chemotherapeutic regimens were proposed as
advantageous for pretreated ENKTL.16 Our patientwas treated with localized radiation, R-CHOP, R-ICE,
intrathecal chemotherapy, and autologous stem cell
transplant. He survived only 29 months after diag-
nosis, which is almost twice as long as reported
median overall survival.
Interestingly, R-CHOP, in the case of our
patient, provided a 6-month remission. There is a
modern notion to include B-cell depletion strategies
in the treatment of EBV1 lymphoproliferative disor-
ders, not of B-cell origin, based on the fact the EBV
is harbored mainly in resting B lymphocytes.20
During the T lymphocyte depletion, EBV-infected
B cells have a higher potential for proliferation
because of the diminishing of suppressive
mechanisms. It would be interesting to know if a
combination of rituximab with pegaspargase-based
chemotherapy would improve overall survival,
although its relevance in a case such as this in
which the EBV is at least largely in the T-cells is
uncertain.
Cutaneous manifestations of ENKTL must be
considered in the case of rapidly progressing
cutaneous ulcers even if the infiltrate is CD56.
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